Lotus Pharm vs StemCyte: monthly revenue

Monthly revenue and year-on-year change for Lotus Pharm (1795) and StemCyte (4178) over the past 13 months. The chart compares year-on-year growth rather than amounts, since the companies differ in size.

Year-on-year change

━ Lotus Pharm ━ StemCyte

0%+226%-29%25/1026/0126/0426/0726/10

Monthly revenue history

MonthLotus PharmYoYStemCyteYoY
Oct 2026NT$2.13 billion-22.5%NT$33 million+16.0%
Sep 2026NT$2.77 billion+128.0%NT$30.7 million+28.2%
Aug 2026NT$2.11 billion+81.7%NT$32 million+9.0%
Jul 2026NT$2.49 billion+3.9%NT$32.4 million+13.7%
Jun 2026NT$3.4 billion+225.5%NT$33.8 million+4.9%
May 2026NT$2.32 billion+105.8%NT$30.2 million+5.0%
Apr 2026NT$3.09 billion+19.9%NT$32.7 million+29.7%
Mar 2026NT$4.35 billion+173.6%NT$27.8 million-27.1%
Feb 2026NT$2.24 billion+131.5%NT$29.1 million-13.6%
Jan 2026NT$2.05 billion-5.5%NT$30.9 million-4.5%
Dec 2025NT$2.44 billion+66.9%NT$27.4 million-29.1%
Nov 2025NT$1.06 billion-0.2%NT$30.9 million-3.3%
Oct 2025NT$2.75 billion+46.0%NT$28.5 million-13.3%

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16